All In Biotech

Drug Trial Radar · NCT04755283

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 1,287 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,287

Actual

Start

Feb 2, 2021

Primary completion

Feb 15, 2024

Study completion Dec 29, 2028

Sponsor

Lead sponsor
Anthos Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Novartis Pharmaceuticals
First posted
Feb 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

Conditions

  • Atrial Fibrillation (AF)
  • Stroke

Interventions

  • AbelacimabBiological

    Abelacimab provided as liquid in vial (150 mg/mL)

  • RivaroxabanDrug

    Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate of the First Occurrence of Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major Bleeding or Clinically Relevant Non-Major (CRNM) Bleeding EventsTime frame: Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.

Locations

92 sites in 7 countries. Site status is shown where the registry gives one.

  • Anthos Investigative Site

    Huntsville, Alabama

  • Anthos Investigative Site

    Mobile, Alabama

  • Anthos Investigative Site

    Stamford, Connecticut

  • Anthos Investigative Site

    Clearwater, Florida

  • Anthos Investigative Site

    Daytona Beach, Florida

  • Anthos Investigative Site

    Largo, Florida

  • Anthos Investigative Site

    Safety Harbor, Florida

  • Anthos Investigative Site

    Saint Augustine, Florida

  • Anthos Investigative Site

    Johns Creek, Georgia

  • Anthos Investigative Site

    Owensboro, Kentucky

  • Anthos Investigative Site

    Baltimore, Maryland

  • Anthos Investigative Site

    Salisbury, Maryland

  • Anthos Investigative Site

    Framingham, Massachusetts

  • Anthos Investigative Site

    Haverhill, Massachusetts

  • Anthos Investigative Site

    Lansing, Michigan

  • Anthos Investigative Site

    Sewell, New Jersey

  • Anthos Investigative Site

    Poughkeepsie, New York

  • Anthos Investigative Site

    Southampton, New York

  • Anthos Investigative Site

    Lenoir, North Carolina

  • Anthos Investigative Site

    Fargo, North Dakota

  • Anthos Investigative Site

    Oklahoma City, Oklahoma

  • Anthos Investigative Site

    Camp Hill, Pennsylvania

  • Anthos Investigative Site

    Kingsport, Tennessee

  • Anthos Investigative Site

    Kingwood, Texas

  • Anthos Investigative Site

    Odessa, Texas

  • Anthos Investigative Site

    Tomball, Texas

  • Anthos Investigative Site

    Falls Church, Virginia

  • Anthos Investigative Site

    Manassas, Virginia

  • Anthos Investigative Site

    Cambridge, Ontario, Canada

  • Anthos Investigative Site

    Greater Sudbury, Ontario, Canada

  • Anthos Investigative Site

    Oshawa, Ontario, Canada

  • Anthos Investigative Site

    Greenfield Park, Quebec, Canada

  • Anthos Investigative Site

    Montreal, Quebec, Canada

  • Anthos Investigative Site

    Brandýs nad Labem, Central Bohemia, Czechia

  • Anthos Investigative Site

    Poděbrady, Central Bohemia, Czechia

  • Anthos Investigative Site

    Příbram, Central Bohemia, Czechia

  • Anthos Investigative Site

    Slaný, Central Bohemia, Czechia

  • Anthos Investigative Site

    Mariánské Lázně, KA, Czechia

  • Anthos Investigative Site

    Trutnov, KR, Czechia

  • Anthos Investigative Site

    Liberec, LB, Czechia

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.